MyFinsight
Home
Blog
About
Contact
Download
Download image
Share-based compensation
$72,291K
Proceeds from term loans
$122,500K
Accrued expenses
$27,106K
Royalties payable
$1,988K
Tax incentive
receivable
-$1,874K
Accretion of ripsa
$1,654K
Amortization of debt issuance
costs
$1,346K
Depreciation
$588K
Loss on
extinguishment of debt
-$407K
Proceeds from exercise of
share options
$10,108K
Net cash provided
by/(used in) operating...
$19,000K
Net cash provided by
financing activities
$18,400K
Effect of exchange rate
changes on cash and cash...
$1,394K
Canceled cashflow
$88,254K
Canceled cashflow
$114,208K
Net change in cash
and cash...
$38,259K
Canceled cashflow
$535K
Accounts receivable
$51,362K
Income taxes
-$9,454K
Accounts payable
-$7,832K
Inventory
$6,301K
Net income/(loss)
-$4,398K
Prepaid expenses
$3,859K
Other current
liabilities
-$2,488K
Foreign exchange
(gain)/loss
$1,567K
Other current assets
$572K
Operating lease
liabilities
-$421K
Repurchase of ripsa
$109,921K
Payments of withholding
taxes from...
$4,287K
Net cash used in
investing activities
-$535K
Purchases of furniture and
equipment
$535K
Back
Back
Cash Flow
source: myfinsight.com
Verona Pharma plc (VRNA)
Verona Pharma plc (VRNA)